Caractéristiques pharmacologiques et cliniques des inhibiteurs directs du facteur Xa : rivaroxaban, apixaban, edoxaban et betrixaban

McLean, 1967, (1890–1957), discoverer of heparin, JAMA, 201, 770, 10.1001/jama.1967.03130100068022 Link, 1959, The discovery of dicumarol and in sequels, Circulation, 19, 97, 10.1161/01.CIR.19.1.97 Weitz, 2012, New antithrombotic drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines, Chest, 141, e120S, 10.1378/chest.11-2294 Samama, 2011, Hétérogénéité pharmacologique des nouveaux anticoagulants, J Mal Vasc, 36, S10, 10.1016/S0398-0499(11)70002-6 Halabi, 2007, Effect of hepatic impairment on the pharmacodynamics and tolerability of rivaroxaban – an oral, direct factor Xa inhibitor, J Thromb Haemost, 5, 635 Kubitza, 2006, Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban – an oral, direct Factor Xa inhibitor, are not affected by aspirin, J Clin Pharmacol, 46, 981, 10.1177/0091270006292127 Ericksson, 2011, Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip of knee arthroplasty, Thromb Res, 130, 147, 10.1016/j.thromres.2011.12.005 Mega, 2009, Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomized, double-blind, phase II trial, Lancet, 374, 29, 10.1016/S0140-6736(09)60738-8 Eriksson, 2008, Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty, N Engl J Med, 358, 2765, 10.1056/NEJMoa0800374 Kakkar, 2008, Extended duration rivaroxaban versus short term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double blind, randomised controlled trial, Lancet, 372, 31, 10.1016/S0140-6736(08)60880-6 Lassen, 2008, Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty, N Engl J Med, 358, 2776, 10.1056/NEJMoa076016 Turpie, 2009, Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty: a randomised trial, Lancet, 373, 1673, 10.1016/S0140-6736(09)60734-0 Patel, 2011, Rivaroxaban versus warfarin in non-valvular atrial fibrillation, N Engl J Med, 365, 883, 10.1056/NEJMoa1009638 ROCKET AF Study Investigators, 2010, Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: rationale and design of the ROCKET AF study, Am Heart J, 159, 340, 10.1016/j.ahj.2009.11.025 Büller, 2008, A dose-ranging study evaluating once daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study, Blood, 112, 2242, 10.1182/blood-2008-05-160143 Romualdi, 2011, Oral rivaroxaban after symptomatic venous thromboembolism: the continued treatment study (Einstein-extension study), Expert Rev Cardiovasc Ther, 9, 841, 10.1586/erc.11.62 EINSTEIN–PE Investigators, 2012, Oral rivaroxaban for the treatment of symptomatic pulmonary embolism, N Engl J Med, 366, 1287, 10.1056/NEJMoa1113572 Cohen, 2013, Rivaroxaban for thromboprophylaxis in acutely ill medical patients, N Engl J Med, 368, 1945, 10.1056/NEJMoa1111096 Mega Jl, 2012, Rivaroxaban in patients with a recent acute coronary syndrome, N Engl J Med, 366, 9, 10.1056/NEJMoa1112277 Wang, 2009, In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition and induction studies, Drug Metab Dispos, 38, 448, 10.1124/dmd.109.029694 Lassen, 2009, Apixaban or enoxaparin for thromboprophylaxis after knee replacement, N Engl J Med, 361, 504, 10.1056/NEJMoa0810773 Lassen, 2010, Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomized double-blind trial, Lancet, 375, 807, 10.1016/S0140-6736(09)62125-5 Lassen, 2010, Apixaban versus enoxaparin for thromboprophylaxis after hip replacement, N Engl J Med, 363, 2487, 10.1056/NEJMoa1006885 ClinicalTrials.gov ID: NCT00643201, first received March 20, 2008, last updated on May 17, 2011. Agnelli, 2013, Apixaban for extended treatment of venous thromboembolism, N Engl J Med, 368, 699, 10.1056/NEJMoa1207541 Agnelli, 2013, Oral apixaban for the treatment of acute venous thromboembolism, N Engl J Med, 369, 799, 10.1056/NEJMoa1302507 Connolly, 2011, Apixaban in patients with atrial fibrillation (AVERROES Study), N Engl J Med, 364, 806, 10.1056/NEJMoa1007432 Granger, 2011, Apixaban versus warfarin in patients with atrial fibrillation, N Engl J Med, 365, 981, 10.1056/NEJMoa1107039 Lopes, 2010, Apixaban for Reduction In Stroke and Other ThromboemboLic Events in atrial fibrillation (ARISTOTLE) trial: design and rationale, Am Heart J, 159, 331, 10.1016/j.ahj.2009.07.035 Martin, 2012, Management of venous thromboembolism in patients with advanced gastrointestinal cancers: what is the role of novel oral anticoagulants?, Thrombosis, 2012, 758385, 10.1155/2012/758385 Goldhaber, 2011, Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients, N Engl J Med, 365, 2167, 10.1056/NEJMoa1110899 Alexander, 2011, Apixaban with antiplatelet therapy after acute coronary syndrome, N Engl J Med, 365, 699, 10.1056/NEJMoa1105819 Camm, 2011, Edoxaban: a new oral direct factor xa inhibitor, Drugs, 71, 1503, 10.2165/11595540-000000000-00000 Weitz, 2010, Randomised, parallel-group, multicenter, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation, Thromb Haemost, 104, 633, 10.1160/TH10-01-0066 2013, Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism, N Engl J Med, 369, 1406, 10.1056/NEJMoa1306638 Zhang, 2009, Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N. N-dimethylcarbamimidoyl) benzamido)-5methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitors, Bioorg Med Chem Lett, 19, 2179, 10.1016/j.bmcl.2009.02.111 Turpie, 2009, A randomized evaluation of betrixaban an oral factor Xa inhibitor for prevention of thromboembolism events after total knee replacement (EXPERT), Thromb Haemost, 101, 68, 10.1160/TH08-07-0460 Connolly, 2013, Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2 randomized dose-ranging study (EXPLORE-Xa), Eur Heart J, 34, 1498, 10.1093/eurheartj/eht039 Samama, 2011, Laboratory assessment of new anticoagulants, Clin Chem Lab Med, 49, 761, 10.1515/CCLM.2011.134 Samama, 2011, Deux nouveaux anticoagulants : dabigatran et rivaroxaban. Leur impact sur les examens de laboratoire, Biotribune, 38, 16 Gouin-Thibault, 2011, Nouveaux anticoagulants par voie orale : quelle place pour les analyses de biologie médicale ?, Sang Thrombose Vaisseaux, 23, 8 Gerotziafas, 2012, Optimisation of the assays for the measurement of clotting factor activity in the presence of rivaroxaban, Thromb Res, 129, 101, 10.1016/j.thromres.2011.09.004 Douxfils, 2013, Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide, Thromb Haemost, 110, 283, 10.1160/TH12-12-0898 Samama, 2012, Do new oral anticoagulants require laboratory monitoring? The clinician point of view, Throm Res, 130, S88, 10.1016/j.thromres.2012.08.286 Samama, 2010, Assessment of laboratory assays to measure rivaroxaban – an oral, direct factor Xa inhibitor, Thromb Haemost, 103, 815, 10.1160/TH09-03-0176 Tripodi, 2011, The International Normalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in vitro study, J Thromb Haemost, 9, 226, 10.1111/j.1538-7836.2010.04106.x Freyburger, 2011, Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement, Thromb Res, 127, 457, 10.1016/j.thromres.2011.01.001 Samama, 2013, Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery: an observational study, J Thromb Thrombolysis, 35, 140, 10.1007/s11239-012-0803-x Samama, 2012, Evaluation of the prothrombin time for measuring rivaroxaban plasma concentrations using calibrators and controls: results of a multicenter field trial, Clin Appl Thromb Hemost, 18, 150, 10.1177/1076029611426282 Samama, 2012, for the rivaroxaban anti-FXa chromogenic assay field trial lab. Evaluation of the anti-Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls, Thromb Haemost, 107, 379, 10.1160/TH11-06-0391 Samama, 2010, An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma, Thromb Haemost, 104, 1078, 10.1160/TH10-03-0204 Pernod, 2012, Questions-réponses sur l’utilisation du rivaroxaban dans le traitement de la maladie thromboembolique veineuse, J Mal Vasc, 37, 300, 10.1016/j.jmv.2012.09.003 Effective practical management of patients with thromboembolic disorders using rivaroxaban. Symposium at the 58th Annual Meeting of the Scientific and Standardization Committee of the ISTH – Liverpool (UK) June 28th, 2012. Lu, 2013, A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa, Nat Med, 19, 446, 10.1038/nm.3102 Van Ryn J, Litzenburger T, Schurer J, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany. Reversal of anticoagulant activity of dabigatran and dabigatran-induced bleeding in rats by a specific antidote (antibody fragment). AHA 2013 [abstract 9928]. Marlu, 2012, Reversal of anticoagulant effect of dabigatran and rivaroxaban by non-specific reversal agents: a randomized crossover ex vivo study in healthy volunteers, Thromb Haemost, 108, 217, 10.1160/TH12-03-0179 Lillo-Le Louët, 2012, Life-threatening bleeding in 4 patients with an unusual excessive response to dabigatran implications for emergency surgery and resuscitation, Thromb Haemost, 108, 583, 10.1160/TH12-03-0149 Rohatagi, 2012, Characterisation of exposure versus response of edoxaban in patients undergoing total hip replacement surgery, Thromb Haemost, 108, 887, 10.1160/TH12-03-0184 Raskob, 2013, Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-VTE study, J Thromb Haemost, 11, 1287, 10.1111/jth.12230 Sié, 2011, [Surgery and invasive procedures in patients on long-term treatment with oral direct thrombin or factor Xa inhibitors], Ann Fr Anesth Reanim, 30, 645, 10.1016/j.annfar.2011.06.018 Pernod, 2013, Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) – March 2013, Arch Cardiovasc Dis, 106, 382, 10.1016/j.acvd.2013.04.009 Samama, 2013, Accidents hémorragiques des nouveaux anticoagulants, J Mal Vasc, 38, 259, 10.1016/j.jmv.2013.05.005 Mirdamadi, 2013, Dabigatran: a direct thrombin inhibitor, can be a life-saving treatment in heparin-induced thrombocytopenia, ARYA Atheroscler, 9, 112 Bhatt, 2013, Nonheparin anticoagulants for heparin-induced thrombocytopenia, N Engl J Med, 368, 2333, 10.1056/NEJMc1303640